Title: International Biotech Leaders Strengthen Collaborations with Chinese Pharmaceutical Firms

On Thursday, May 24, 2018, a scientist examined specimens within the research and development facility of BeiGene Ltd. in Beijing, China. Listed on the Nasdaq, BeiGene commands a valuation of approximately $9 billion, representing a roughly sevenfold increase from its initial public offering in 2016. The company’s innovative cancer therapies are currently drawing significant international attention. (Photographer: Gilles Sabrie/Bloomberg via Getty Images)

Source: Bloomberg Generated at: 2026-06-02 13:02:15 UTC